Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression

Mandakh Bekhbat, Emory University
Karen Chu, Emory University
Ngoc-Anh Le, Atlanta VA Medical Center
Bobbi J. Woolwine, Emory University
Ebrahim Haroon, Emory University
Andrew Miller, Emory University
Jennifer Felger, Emory University

Journal Title: Psychoneuroendocrinology
Volume: Volume 98
Publisher: Pergamon-Elsevier Science Ltd. | 2018-12-01, Pages 222-229
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1016/j.psyneuen.2018.09.004
Permanent URL: https://pid.emory.edu/ark:/25593/vhxc6

Final published version: http://dx.doi.org/10.1016/j.psyneuen.2018.09.004

Copyright information:
© 2018 Elsevier Ltd
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Accessed December 7, 2023 11:44 AM EST
Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression

Mandakh Bekhbat, PhD¹, Karen Chu, MD¹, Ngoc-Anh Le, PhD², Bobbi J. Woolwine, MSW¹, Ebrahim Haroon, MD¹,³, Andrew H. Miller, MD¹,³, and Jennifer C. Felger, PhD¹,³

¹Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA 30322
²Biomarker Core Laboratory, Atlanta VAMC, Decatur, GA, 30033
³The Winship Cancer Institute, Emory University, Atlanta, GA 30322

Abstract

The tumor necrosis factor (TNF) antagonist infliximab was previously found to reduce depressive symptoms in patients with treatment-resistant major depression (TRD) who exhibited high baseline inflammation, as reflected by plasma C-reactive protein (CRP) >5mg/L. Further predictors of antidepressant response to infliximab included differential expression of peripheral blood gene transcripts that were related not only to inflammation but also to glucose and lipid metabolism. To determine whether plasma biomarkers of glucose and lipid metabolism were similarly associated with antidepressant response to infliximab and with relevant gene transcripts, we measured concentrations of glucose, insulin, and protein hormones that regulate glucose homeostasis and metabolism (leptin, resistin, and adiponectin), as well as cholesterol, triglycerides, and non-esterified fatty acids (NEFA), in medically-stable TRD outpatients at baseline and 2 weeks after the first infusion of infliximab (n=26) or placebo (n=26). Treatment response was defined as 50% reduction in depressive symptoms at any point during the 12-week trial. We found that baseline cholesterol (total, low-density lipoprotein [LDL], and non-high-density lipoprotein [non-HDL]), triglycerides and NEFA were elevated in patients who exhibited an antidepressant response to infliximab (all p<0.05) but not placebo (all p>0.299). HDL and non-HDL cholesterol concentrations also correlated with two lipid-related gene transcripts that were predictive of antidepressant response (r=0.33 to 0.39, p<0.05). Although not associated with response to infliximab, resistin correlated with numerous glucose-related transcripts (r=−0.32 to 0.37, p<0.05) and was higher at 2 weeks post-infusion in patients treated with infliximab compared to placebo (p=0.028). Concentrations of cholesterol (total, LDL, HDL, non-HDL) were also lower at 2 weeks in patients treated with infliximab compared to placebo, but only in those...
patients with CRP >5mg/L at baseline (all p<0.05). These results are consistent with previous work showing that high inflammation in patients with depression is associated with metabolic alterations, which together predict response to both traditional and experimental antidepressant therapies. Additionally, our findings suggest a causal relationship between increased inflammation and high cholesterol in depression, as a single infusion of infliximab reduced cholesterol in TRD patients with high CRP compared to placebo.

**Keywords**

inflammation; depression; tumor necrosis factor; C-reactive protein; lipids; glucose; metabolism

**Introduction**

Depression is a heterogenous and widespread disorder with a lifetime prevalence >20% (Hasin et al., 2018) that confers increased risk for medical illnesses which are known to be associated with inflammation, obesity and/or metabolic dysregulation including cardiovascular disease, diabetes, and cancer (Currier and Nemeroff, 2014; Musselman et al., 2003; Musselman et al., 1998). In this regard, 30–50% of patients with depression are reported to have high levels of inflammatory markers, including the acute phase reactant C-reactive protein (CRP), as well as high body mass index (BMI), and/or markers of metabolic dysregulation, all of which may predispose patients to the development of co-morbid medical illnesses (Felger et al., 2016; Rapaport et al., 2016; Rethorst et al., 2014; Shelton et al., 2015). Standard antidepressant therapies fail in over 30% of depressed patients, and those with high inflammation and/or high BMI are particularly resistant (Cattaneo et al., 2013; Haroon et al., 2018; Rush, 2007; Uher et al., 2009). Accordingly, there has been recent interest in better understanding the role of inflammation and metabolic changes in depression and the potential for novel therapeutic strategies that may be targeted to patients with high CRP and/or BMI (Dutheil et al., 2016; Miller et al., 2017; Shelton and Miller, 2010).

Inflammatory cytokines that are produced in the periphery are known to access the central nervous system and to affect neurotransmitters and neural circuits that contribute to the behavioral symptoms of depression (Capuron et al., 2017; Felger, 2018; Felger and Treadway, 2017; Haroon et al., 2017). Activated macrophages that reside in adipose tissue are thought to be a major source of these cytokines in patients with depression and high BMI (Capuron et al., 2017; Park et al., 2005; Weisberg et al., 2003). Conversely, cytokine signaling in adipose tissue - and particularly tumor necrosis factor (TNF) activity - in turn promotes metabolic dysregulation (Borst, 2004; Hotamisligil et al., 1994; Nieto-Vazquez et al., 2008; Popa et al., 2007), and may exert feed-forward consequences on adiposity, depression and risk for inflammatory and metabolic diseases. Despite growing evidence of bidirectional relationships between inflammation and metabolic changes (Capuron et al., 2017; Kiecolt-Glaser et al., 2017), little research has been done to examine the contribution of inflammation as a potential driver of metabolic dysregulation in patients with MDD.
TNF is often regarded as a central regulator of inflammation, and is a target of several FDA-approved anti-inflammatory drugs including infliximab (Lis et al., 2014). We previously published that inhibition of TNF signaling with infliximab reduced depressive symptoms in patients with treatment resistant depression (TRD), but only in patients who had high baseline plasma CRP (>5 mg/L). TNF antagonism with infliximab also lowered concentrations of CRP and other inflammatory cytokines, which may be essential to its observed antidepressant effect in patients with high baseline CRP (Raison et al., 2013). Analysis of gene expression signatures in infliximab-responders showed that baseline transcripts predictive of antidepressant response to infliximab were not only related to inflammation and TNF-signaling but also to glucose and lipid metabolism, indicating that metabolic dysregulation may have been present in patients with high inflammation who were most responsive to infliximab (Mehta et al., 2013). Furthermore, a single dose of infliximab modified expression levels of both inflammatory and metabolic-related gene transcripts 2 weeks post-infusion in responders, suggesting that reducing inflammation may have also improved metabolic function in these patients (Mehta et al., 2013). With regard to the metabolic effects of TNF blockade in previous studies, infliximab has been shown to improve indices of glucose and lipid metabolism in patients with rheumatoid arthritis (Gonzalez-Gay et al., 2006; Kiortsis et al., 2005; Tam et al., 2007), while no changes were reported in patients receiving infliximab treatment for inflammatory bowel disease (Gentile et al., 2002; Steiner et al., 2008). However, the relationship between circulating markers of glucose and lipid metabolism and antidepressant response to infliximab in patients with TRD is not fully understood, and the extent to which baseline inflammation (CRP) moderates this relationship remains to be determined.

This exploratory study measured plasma biomarkers related to glucose and lipid metabolism to determine whether they were 1) associated with antidepressant response to infliximab, 2) related to gene transcripts previously identified to be predictive of infliximab response and/or 3) affected by infliximab compared to placebo 2 weeks after a single infusion in the group as whole or in patients with high baseline inflammation (CRP >5 mg/L). A panel comprised of glucose, insulin, and the adipokines leptin, resistin, and adiponectin, which are associated with glucose and insulin metabolism as well as depression (Bryson et al., 1999; Lehto et al., 2010; Li et al., 2016; Singh and Saxena, 2010), was selected and assessed as markers of glucose synthesis and metabolism. The panel related to lipid metabolism included total cholesterol, low and high-density lipoprotein (LDL, HDL) cholesterol, non-HDL cholesterol, triglycerides, and non-esterified fatty acids (NEFA).

**Materials and Methods**

**Participants:**

Peripheral blood plasma and RNA samples were collected during a randomized, double-blind trial of infliximab versus placebo in TRD patients, defined as patients with MDD or bipolar disorder who were depressed and non-responsive to antidepressant treatment as determined by a score ≥2 on the Massachusetts General Hospital Staging (MGH-S) method in the current episode (Raison et al., 2013). Participants were recruited via local television, radio, and newspaper advertisements and included males and females aged 25–60 years who

*Psychoneuroendocrinology. Author manuscript; available in PMC 2019 December 01.*
were on a consistent antidepressant regimen or off antidepressant therapy for at least 4 weeks prior to baseline. To balance the number of male and female participants and to equalize levels of inflammation across groups, treatment assignment was stratified by sex and CRP (>2mg/L versus <2mg/L). Groups were stratified by a CRP concentration of 2 mg/L, because it represents the median value in the “average” relative risk category of inflammation (1–3 mg/L) as delineated by the American Heart Association and the Centers for Disease Control and Prevention (Pearson, 2003). To be enrolled, subjects had to exhibit moderate severity of depression as determined at screening by a score ≥4 on the 16 item Quick Inventory of Depressive Symptomatology Self Report. Antidepressant regimens were required to remain stable throughout the study and could include conventional antidepressant medications, mood stabilizers, antipsychotic medication, stimulants, and benzodiazepines. Exclusion criteria included any autoimmune disorder (confirmed by laboratory testing); history of tuberculosis (confirmed by chest X-ray, skin, and/or blood testing) or high risk of tuberculosis exposure; hepatitis B or C or human immunodeficiency virus infection (confirmed by laboratory testing); evidence of active fungal infection; history of recurrent viral or bacterial infections; history of cancer excluding basal cell or squamous cell carcinoma of the skin (fully excised with no recurrence); unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (determined by medical history, physical examination and laboratory testing); history of schizophrenia (determined by Structured Clinical Interview [SCID] for DSM-IV); active psychotic symptoms of any type; substance abuse/dependence within the past 6 months (determined by SCID); active suicidal ideation determined by a score ≥3 on item #3 on the 17-item Hamilton Depression Rating Scale (HAM-D-17) and/or a score <28 on the Mini-Mental State Exam. All subjects provided written informed consent to the study, and all study procedures were approved by the Emory University Institutional Review Board. The study is registered in ClinicalTrials.gov, Identifier: NCT00463580. Demographic and clinical variables between the infliximab and placebo groups were well-matched with no significant differences (Mehta et al., 2013; Raison et al., 2013).

Clinical Assessments:

The diagnosis of depression was made using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), as assessed by the SCID. Depression severity was measured by the HAM-D-17 at baseline and at Weeks 1, 2, 3, 4, 6, 8, 10, and 12. Treatment response was defined as a 50% reduction in the HAM-D-17 at any point during the 12-week study.

Infliximab and Placebo Infusion Procedures:

All subjects were administered either infliximab (5mg/kg, n=26) or placebo (n=26) through an indwelling catheter at the Emory Division of Digestive Diseases at 3 separate time points (baseline, 2 weeks, and 6 weeks). Infliximab infusion dosing protocol and scheduling were matched to the standard intravenous induction routine for the treatment of inflammatory bowel disease. Infliximab or placebo was dispensed by independent pharmacists in a 250ml saline bag according to a computer-generated randomization list, blocked in units of 4, and provided by a study statistician. The saline-dissolved placebo was matched to infliximab in color and consistency. Infliximab and placebo were provided free-of-charge by Centocor.
Ortho Biotech Services (Horsham, PA). For subjects exhibiting evidence of infection, infusions were delayed until symptoms resolved and/or appropriate treatment was initiated. Patients were not allowed to take non-steroidal or steroidal anti-inflammatory medications during the study except for aspirin 81 mg per day if medically indicated. Medications for hypertension, diabetes, hypothyroidism, allergies, infections, and other medical conditions were allowed as dictated by the patients’ treating physicians. All study staff remained blinded to group assignment throughout the trial.

**Blood collection:**

Whole blood was collected through indwelling catheters after participants had at least 30 minutes of rest. For plasma isolation, blood was collected into EDTA-containing vacutainer tubes approximately three hours from the patient’s last food intake at baseline (3pm ± 1 hour), and immediately prior to the second infusion at Week 2 (~10am-2pm). Plasma was obtained by centrifugation at 1000 x g for 10 minutes at 4°C, aliquoted into siliconized polypropylene tubes, and stored at −80°C until assay. Whole blood for gene expression analysis was collected in Tempus Blood RNA Tubes (Applied Biosystems, Carlsbad, CA) at baseline (9 am) and immediately prior to the second infusion on Week 2 and stored at -80°C until RNA extraction.

**Measurement of metabolic panels and CRP:**

Plasma markers of glucose and lipid metabolism were measured in the Biomarker Core Lab of the Atlanta Research and Education Foundation. Plasma leptin, resistin, and adiponectin were measured by ELISA (Boster Biological, Pleasanton, CA). Assay detection limits were 10 pg/ml, 3 pg/ml and 0.06 ng/ml, respectively. Plasma glucose (colorimetric), insulin (immunoturbidimetric), lipids (enzymatic) and high sensitivity (hs)-CRP (immunoturbidimetric) were assayed using reagents from Sekisui Diagnostics (Exton, PA) implemented on the AU480 chemistry analyzer (Beckman Coulter). Mean inter- and intra-assay coefficients of variation were reliably <10% (Felger et al., 2016; Le et al., 2000; Mehta et al., 2013; Raison et al., 2013).

**Measurement of gene expression:**

Peripheral whole blood gene expression at baseline was analyzed as described previously (Mehta et al., 2013), and 148 transcripts were identified to be significantly associated with antidepressant response to infliximab. Functional annotation of these transcripts within pathways as assessed by MetaCore (GeneGo Inc., St. Joseph, MI) or the Wikipathways tool via the Webgestalt interface (Pico et al., 2008) found 5 genes associated with glycolysis and gluconeogenesis and 3 genes associated with lipid metabolism (cholesterol and sphingolipid transport) to be the most predictive gene transcripts (Mehta et al., 2013). In the current study, we assessed whether plasma markers related to glucose and lipid metabolism correlated with these 8 genes that were previously associated with antidepressant response to infliximab.

**Statistics:**

Descriptive statistics (means, standard deviation, and standard error) were used to characterize demographic characteristics and continuous variables over time. Plasma
markers were examined for normality and the presence of outliers. Non-normal markers were natural log (ln) transformed for parametric statistics, consistent with previous analyses (Haroon et al., 2014; Haroon et al., 2016; Raison et al., 2009; Torres et al., 2013).

Multivariate linear regression models were used to identify baseline plasma markers related to glucose or lipid metabolism (separately) that differed between patients who did or did not exhibit an antidepressant response to either infliximab or placebo. Principal components analysis (PCA) was used as a data reduction strategy to identify clusters of like markers at baseline that were associated with response to infliximab (as a categorical variable). Varimax rotation with Kaiser Normalization was used to simplify the factor structure and obtain more meaningful and interpretable data. Factors were determined by Eigen values > 1, and only individual variable contributions of >0.3 qualified for loading a component (Felger et al., 2018; Grimsholm et al., 2005). The resulting Bartlett factor scores were subsequently entered into logistic regression and general linear models (Felger et al., 2018) with and without clinical covariates (age, sex, race, BMI, use of psychiatric and psychotropic medications and use of cholesterol-/diabetes-controlling medications) to determine whether clusters of markers significantly predicted response to infliximab, and whether they were significantly different in infliximab responders compared to non-responders. Relationships between baseline plasma markers of glucose and lipid metabolism and gene transcripts that were previously found to be predictive of response to infliximab and associated with glucose (n=3) and cholesterol (n=5) metabolism (Mehta et al., 2013) were assessed by correlation. The Benjamini–Hochberg step-up procedure was used to control for multiple comparisons, and relationships that remained significant were assessed in linear regression models with relevant covariates. Multivariate repeated measures general linear models (GLM), with and without clinical covariates (see above), were used to assess the effects of a single infusion of infliximab at 2 weeks compared to placebo, and whether potential treatment effects over time were different in patients with plasma CRP >5 mg/L. To determine which markers differed at 2 weeks between infliximab- and placebo-treated patients with and without CRP >5 mg/L while controlling for baseline concentrations of each marker, multivariate general estimating equation (GEE) models were employed. Individual markers were converted to Z scores for graphing to be able to visualize all markers on the same graphs. Tests of significance were two-tailed, α <0.05, and all statistical analyses were conducted in IBM SPSS Statistics 24.

Results

Demographics and Clinical Variables

Source data were drawn from a 12-week clinical trial including 60 individuals administered infliximab (n=30) or placebo (n=30). Biomarkers of glucose and cholesterol metabolism were available from 52 individuals, 26 patients treated with infliximab (n=13 responders and n=13 non-responders) and 26 treated with placebo (n=12 responders and n=14 non-responders). One patient did not have gene expression data available, and thus 51 patients were included in analyses involving genes. Demographic and clinical variables in the infliximab- and placebo-treated groups were well-matched with no significant differences in the sample as a whole (n=60) (Raison et al., 2013) and in the 52 patients included in this study (data not shown). Distributions and comparisons of the demographic and clinical
variables between treatment responders and non-responders for both the infliximab- and placebo-treated groups are shown in Table 1. No differences in gender, age, ethnicity, BMI, CRP, baseline HAM-D-17 depression scores, or the number of individuals on current antidepressants, mood stabilizers, antipsychotic medicines, and psychotropic medicines were observed between the responders and non-responders in either treatment group (all p>0.05). Baseline concentrations of plasma glucose- and lipid-related biomarkers by CRP level are shown in Supplemental Table 1.

**Relationships between Baseline Biomarkers of Glucose and Lipid Metabolism and Infliximab Response**

In multivariate analysis, baseline concentrations of plasma glucose, insulin, and peptide hormones related to glucose metabolism and homeostasis (leptin, resistin and adiponectin) were not significantly higher in patients who exhibited an antidepressant response to either infliximab (all p>0.197) or placebo (all p>0.246) (see Figure 1a,b for mean Z scores of plasma markers). However, a significant antidepressant response by CRP >5 mg/L interaction was observed for glucose in the infliximab-treated patients (F[1,23]=4.41, p=0.049), which did not remain significant when adjusting for clinical covariates (age, sex, race, BMI, use of psychiatric and psychotropic medications, and use of cholesterol controlling medications; p=0.088). PCA revealed two components (Component 1 comprised of glucose, insulin, leptin, and resistin with a negative loading for adiponectin, and Component 2 comprised of glucose and adiponectin) that significantly predicted antidepressant response to infliximab (Supplemental Table 2). Bartlett factor scores from these two components did not significantly predict antidepressant response in logistic regression (both p>0.538) and were not significantly greater in responders compared to non-responders in infliximab-treated patients (both p>0.413).

Multivariate analysis of baseline plasma lipid concentrations (total, LDL, HDL, and non-HDL cholesterol, triglycerides, and NEFA) revealed that concentrations of total (F[1,25]=4.48, p=0.045), LDL (F[1,25]=4.65, p=0.041), and non-HDL (F[1,25]=4.73, p=0.040) cholesterol were significantly elevated in responders to infliximab but not placebo (all p>0.299) (Figure 1c,d). These findings remained significant when controlling for clinical covariates (age, sex, race, BMI, use of psychiatric and psychotropic medications, and use of cholesterol controlling medications; all p<0.05), and the adjusted model revealed that triglycerides (F[1,25]=4.72, p=0.043) and NEFA (F[1,25]=4.57, p=0.046) were also higher at baseline in infliximab responders (Figure 1c,d). PCA revealed two components of lipid-related markers at baseline (Component 1 comprised of positive loadings for baseline total, LDL and non-HDL cholesterol and triglycerides, and Component 2 comprised of positive loadings for total and HDL cholesterol and NEFA) that predicted antidepressant response to infliximab (Supplemental Table 2). Component 1 (but not Component 2, p=0.462) predicted antidepressant response in infliximab-treated patients as determined by logistic regression (OR=3.13, 95% CI: 1.01–9.74, p=0.049), which remained significant when controlling for clinical covariates (p=0.042). Moreover, factor scores for Component 1 were significantly higher in infliximab responders compared to non-responders in models with (F[1,25]=7.52, p=0.013) and without clinical covariates (F[1,25]=4.73, p=0.040).
Correlations between Circulating Biomarkers and Gene Transcripts Related to Glucose and Lipid Metabolism

Baseline plasma biomarkers were correlated with peripheral blood gene transcripts from pathways related to glucose or lipid metabolism that were previously found to be predictive of the antidepressant response to infliximab. In a comparison of the 5 gene transcripts from a pathway related to glucose metabolism, ALDOA was positively correlated with leptin and resistin; ENO2 was negatively correlated with resistin; ENO3 was negatively correlated with resistin and adiponectin; PGAM4 was positively correlated with resistin; and TPI1 was not significantly correlated with any marker related to glucose metabolism or homeostasis (Table 2). Relationships between resistin and gene transcripts for ALDOA, ENO3, and PGAM4 remained significant after correction for multiple comparisons and remained significant after controlling for clinical covariates (age, sex, race, BMI, use of psychiatric and psychotropic medications and use of diabetes medication; all p<0.05). Comparison of 3 gene transcripts from a pathway related to lipid metabolism with circulating lipid markers found that STARD3NL was positively correlated with HDL cholesterol; TSPO2 was positively correlated with non-HDL cholesterol; and LIPA was not significantly correlated with any marker related to lipid metabolism or homeostasis (Table 2). The relationship between TSPO2 and non-HDL cholesterol remained significant after controlling for clinical covariates (p=0.024) but not after correction for multiple comparisons, and the relationship between STARD3NL and HDL cholesterol remained significant after correction for multiple comparisons and after controlling for clinical covariates (p=0.045).

Effects of a Single Infusion of Infliximab versus Placebo on Plasma Biomarkers of Glucose and Lipid Metabolism in Relation to High CRP

To determine whether plasma concentrations of glucose, insulin, or peptide hormones related to glucose metabolism and homeostasis (leptin, resistin, and adiponectin) were differentially affected by a single dose of infliximab compared to placebo at 2 weeks post-infusion, and whether effects of infliximab were dependent on high baseline inflammation as defined by CRP >5 mg/L, multivariate repeated measures GLM was employed. No significant effects for time, treatment, or a time by treatment interaction were observed (all p>0.149). These findings were not affected by the addition of CRP >5 mg/L or clinical covariates to the model. However, multivariate GEE comparing concentrations of glucose and related markers in infliximab- compared to placebo-treated groups at 2 weeks, while controlling for baseline concentrations of each marker, revealed that resistin was significantly greater at 2 weeks in patients administered infliximab compared to placebo (F[1,48]=5.20, p=0.028), a finding that did not depend on an interaction with CRP level (Figure 2a,b) and that remained significant after controlling for clinical covariates (age, sex, race, BMI, use of psychiatric and psychotropic medications, and use of diabetes medications; p=0.035).

To examine the effects at week 2 after a single injection of infliximab compared to placebo and potential interactions with CRP >5 mg/L on plasma concentrations of lipid markers, multivariate repeated measures GLM was employed. Significant effects of time (F[1,43]=20.36, p<0.001) and treatment (F[1,43]=4.71, p=0.036) but not time by treatment interaction were observed (F[1,43]=0.73, p=0.397). Interestingly, however, a significant time
by treatment by CRP >5 mg/L interaction was uncovered (F[1,43]=4.29, p=0.044). Multivariate GEE controlling for baseline concentrations of each marker demonstrated that total (F[1,46]=7.37, p=0.010), LDL (F[1,46]=5.61, p=0.023), HDL (F[1,46]=10.66, p=0.002), and non-HDL (F[1,46]=5.14, p=0.029) cholesterol, but not triglycerides and NEFA (both p>0.320), were significantly lower at 2 weeks in patients administered a single dose of infliximab compared to placebo, but only in patients with CRP >5 mg/L (Figure 2c,d). These findings remained significant when controlling for clinical covariates (age, sex, race, BMI, use of psychiatric and psychotropic medications, use of cholesterol controlling medications; p<0.05).

Discussion

This exploratory study demonstrated that TRD patients who responded to infliximab compared to placebo had significantly higher plasma concentrations of lipid markers (including total, LDL and non-HDL cholesterol, triglycerides and NEFA) at baseline. Additionally, cholesterol (total, LDL, HDL and non-HDL cholesterol), but not triglycerides or NEFA, was significantly lower at 2 weeks post-infliximab compared to placebo, but only in patients who had high plasma CRP (>5 mg/L). Taken together, these findings suggest that TRD patients with high inflammation and elevated levels of lipids and cholesterols are more responsive to the antidepressant effects of infliximab. Moreover, a single infusion of infliximab was previously shown to decrease inflammatory markers like CRP and modify expression of gene transcripts related to TNF signaling (Mehta et al., 2013; Raison et al., 2013), and the current study provides novel evidence that blocking inflammation in TRD patients with high CRP may also decrease circulating cholesterols.

Of the five markers examined related to glucose and insulin regulation, only glucose showed an interaction between response to infliximab and level of CRP, but this finding did not persist when controlling for relevant clinical covariates. PCA revealed a component that was significantly associated with response to infliximab which contained all five markers including a negative loading for adiponectin. Plasma adiponectin has previously been found to negatively correlate with BMI and insulin resistance (Singh and Saxena, 2010; Tschritter et al., 2003), providing biological support for this finding. In addition, a trend was observed for higher concentrations of the other glucose and insulin-related markers at baseline in infliximab responders (Figure 2b) that may have been too variable in this small sample to be detected using general linear models.

Baseline plasma concentrations of resistin were positively correlated with several peripheral blood gene transcripts previously associated with the antidepressant response to infliximab. Furthermore, only resistin was affected 2 weeks after infusion, and was greater in infliximab compared to placebo-treated patients regardless of baseline plasma CRP concentrations. This increase in resistin in infliximab-treated patients is interesting considering that the role of resistin in metabolic disease is controversial and potentially two-sided (Kusminski et al., 2005). Accordingly, findings regarding the effects of infliximab on resistin levels in patients with inflammatory illnesses have been mixed (Frivolt et al., 2017; Miranda-Filloy et al., 2013), yet most studies have reported that infliximab improves other measures of insulin resistance (Bissell et al., 2016; Esser et al., 2015; Gonzalez-Gay et al., 2006; Tam et al., 2017).
2007). Considering that we did not find that infliximab affected other biomarkers relevant to glucose and lipid metabolism, such effects may be limited to patients with inflammatory disorders who have much higher levels of peripheral inflammation and potentially more severe impairments in insulin function.

The findings regarding lipids and cholesterols were highly supportive of the idea that, like high inflammation, dysregulation of cholesterol metabolism and high lipid concentrations are predictive of antidepressant response to infliximab. Although HDL cholesterol was the only lipid marker that was not associated with antidepressant response to infliximab, it did correlate with one of the lipid-related genes that predicted infliximab response, STARD3NL. All of the cholesterols, including HDL, were found to be decreased 2 weeks after infliximab compared to placebo, but only in patients with high inflammation. These findings persisted when clinical covariates including BMI were considered, suggesting that the relationship among lipids, inflammation and antidepressant response to infliximab were not dependent on obesity. Findings that plasma lipids were both higher at baseline in infliximab responders and lower after the initial infusion of infliximab in patients with high CRP further reinforces a potential causal role for inflammation in the metabolic dysregulation observed in patients with depression and high inflammation.

Important limitations of the current study include a small sample size (n=52) and the use of historic plasma samples that were collected at an inconsistent time of day between the baseline and week 2 visit. Specifically, baseline blood was collected in the afternoon ~3hr from the patient’s last food intake and drawn in an inpatient setting. In contrast, week 2 blood was drawn between ~10am and 2pm in an outpatient setting prior to the second infusion, and although time from last food intake was at least ~2–3hr, it was not standardized across patients. Given the rapid fluctuation in markers related to glucose and insulin metabolism, it is possible that the effects of the time of day and the duration of fasting may have been more potent on glucose measures and masked group differences, while also prohibiting calculation of insulin and glucose ratios that require fasting levels. To overcome these limitations, we used statistical approaches to compare biomarker concentrations at week 2 while controlling for baseline levels of each circulating marker (which were more standardized). If lack of predictive findings for plasma markers of glucose metabolism were not due to method constraints, our previous findings that peripheral blood gene transcripts related to glucose metabolism were predictive of infliximab response may reflect changes in energy demands in peripheral blood immune cells due to inflammation rather than the overall metabolic state of the patients. Another limitation was that sleep quality was not controlled for in the current study. Despite these limitations, our findings provide strong evidence that lipid markers are related to treatment response to infliximab and are decreased after a single infusion of infliximab in patients with CRP >5 mg/L.

**Conclusions**

This study indicates a causal role for inflammation in driving aspects of metabolic dysfunction in patients with depression, which can be reversed by blockade of inflammatory cytokines like TNF in association with the resolution of depressive symptoms. These findings also support the recent report from Delgado et al. (2018) concluding that
inflammation contributed to depressive symptoms to a greater extent than markers of metabolic health in a sample of depressed individuals with obesity. These results further suggest that TNF antagonism may be an effective approach to improve both depressive symptoms and metabolic outcomes in patients with TRD and high inflammation. Moreover, this work provides a preliminary framework for future studies examining interactions between inflammation and metabolic dysregulation in patients with psychiatric disorders and the potential for anti-inflammatory therapies to improve both behavioral and medical health outcomes. While these results are potentially intriguing and novel, additional work is needed to solidify relationships between inflammation and lipid metabolism in depression.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgements**

**Funding sources:** This work was supported by grants R21MH0771172, R01MH087604, and R25MH101079 (Dr. Miller), R01MH109637 (Dr. Felger) and R01MH1107033 (Dr. Haroon) from the National Institute of Mental Health; by Centocor Ortho Biotec Services LLC, and by grants BBRF22296 from the Brain and Behavioral Research Foundation and CADF49143 from the Dana Foundation (Dr. Felger). In addition, the study was supported in part by PHS Grants UL1TR000454 from the Clinical and Translational Science Award program, and by the NIH/NCI under award number P30CA138292.

**References**


Felger JC, 2018 Imaging the Role of Inflammation in Mood and Anxiety-related Disorders. Curr Neuropharmacol 16, 533–558. [PubMed: 29173175]


Haroon E, Felger JC, Woolwine BJ, Chen X, Parekh S, Spivey JR, Hu XP, Miller AH, 2014 Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: Preliminary findings. Brain, behavior, and immunity

Haroon E, Fleischer CC, Felger JC, Chen X, Woolwine BJ, Patel T, Hu XP, Miller AH, 2016 Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol Psychiatry


Psychoneuroendocrinology. Author manuscript; available in PMC 2019 December 01.
Highlights

• High plasma CRP previously predicted antidepressant response to infliximab
• Gene transcripts related to glucose and lipid metabolism also predicted this response
• We assessed plasma markers of glucose and lipid metabolism pre and post infliximab
• Cholesterols, triglycerides and NEFA were elevated in responders to infliximab
• Infliximab lowered total, LDL, HDL and non-HDL cholesterol in high CRP patients
Figure 1. Baseline biomarkers of glucose and lipid metabolism and antidepressant response prediction in infliximab vs placebo groups.

Z scores for concentrations of glucose, insulin, and peptide hormones related to glucose metabolism and homeostasis (leptin, resistin, and adiponectin) in placebo (A) and infliximab (B) responders versus non-responders. Z scores for concentrations of total, LDL, HDL and non-HDL cholesterol, triglycerides, and NEFA in placebo (C) and infliximab (D) responders versus non-responders. Data are presented as mean ± standard error. Z scores were employed to be able to visualize all markers on the same graph. p<0.05 responders compared to non-responders. HDL - high-density lipoprotein; LDL - low-density lipoprotein; NEFA - non-esterified fatty acids
Figure 2. Effects of a single infusion of infliximab on plasma biomarkers of glucose and lipid metabolism over time and in relation to CRP.
Z scores for concentrations of glucose, insulin, and peptide hormones related to glucose metabolism and homeostasis (leptin, resistin, and adiponectin) two weeks after infusion of infliximab compared to placebo in patients with low (CRP ≤5 mg/L) (A) or high (CRP >5 mg/L) (B) inflammation. Z scores for concentrations of total, LDL, HDL and non-HDL cholesterol, triglycerides, and NEFA after infusion of infliximab compared to placebo in patients with low (CRP ≤5 mg/L) (C) or high (CRP >5 mg/L) (D) inflammation. Data are presented as mean ± standard error. *p<0.05, **p<0.01 infliximab compared to placebo.
CRP - C-reactive protein; HDL - high-density lipoprotein; LDL - low-density lipoprotein; NEFA - non-esterified fatty acids.
Table 1.

Demographic and clinical characteristics of responders versus non-responders to placebo or infliximab infusion.

<table>
<thead>
<tr>
<th></th>
<th>Placebo Non-responders</th>
<th>Placebo Responders</th>
<th>P-value</th>
<th>Infliximab Non-responders</th>
<th>Infliximab Responders</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(N = 14)</td>
<td>(N = 12)</td>
<td></td>
<td>(N = 13)</td>
<td>(N = 13)</td>
<td></td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>10 [71.4%]</td>
<td>8 [66.7%]</td>
<td>0.79</td>
<td>8 [61.5%]</td>
<td>8 [61.5%]</td>
<td>1.00</td>
</tr>
<tr>
<td>Male</td>
<td>4 [28.6%]</td>
<td>4 [33.3%]</td>
<td></td>
<td>5 [38.5%]</td>
<td>5 [38.5%]</td>
<td></td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>10 [71.4%]</td>
<td>10 [83.3%]</td>
<td>0.59</td>
<td>10 [76.9%]</td>
<td>11 [84.6%]</td>
<td>0.36</td>
</tr>
<tr>
<td>African American</td>
<td>3 [21.4%]</td>
<td>2 [16.7%]</td>
<td></td>
<td>3 [23.1%]</td>
<td>1 [7.7%]</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>1 [7.1%]</td>
<td></td>
<td></td>
<td>1 [7.1%]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td>41.9 [10.3]</td>
<td>46.1 [9.3]</td>
<td>0.29</td>
<td>39.4 [7.6]</td>
<td>45.1 [8.2]</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>BMI</strong></td>
<td>31.3 [7.4]</td>
<td>35.0 [8.0]</td>
<td>0.24</td>
<td>30.1 [8.9]</td>
<td>30.7 [4.4]</td>
<td>0.83</td>
</tr>
<tr>
<td><strong>Baseline CRP (mg/L)</strong></td>
<td>7.8 [11.4]</td>
<td>3.3 [2.8]</td>
<td>0.17</td>
<td>6.3 [7.8]</td>
<td>7.2 [11.3]</td>
<td>0.82</td>
</tr>
<tr>
<td><strong>Baseline HAM-D-17</strong></td>
<td>24.8 [3.6]</td>
<td>23.9 [4.0]</td>
<td>0.57</td>
<td>24.2 [3.8]</td>
<td>24.6 [4.2]</td>
<td>0.81</td>
</tr>
<tr>
<td>Week 12 HAM-D-17</td>
<td>19.8 [6.1]</td>
<td>7.7 [2.8]</td>
<td>0.000</td>
<td>21.9 [7.6]</td>
<td>12.8 [5.9]</td>
<td>0.01</td>
</tr>
<tr>
<td><strong>Current antidepressant</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>8 [57.1%]</td>
<td>9 [75.0%]</td>
<td>0.34</td>
<td>5 [38.5%]</td>
<td>7 [53.8%]</td>
<td>0.43</td>
</tr>
<tr>
<td>No</td>
<td>6 [42.9%]</td>
<td>3 [25.0%]</td>
<td></td>
<td>8 [61.5%]</td>
<td>6 [46.2%]</td>
<td></td>
</tr>
<tr>
<td><strong>Current antipsychotic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>2 [14.3%]</td>
<td>1 [8.3%]</td>
<td>0.64</td>
<td>2 [15.4%]</td>
<td>2 [15.4%]</td>
<td>1.00</td>
</tr>
<tr>
<td>No</td>
<td>12 [85.7%]</td>
<td>11 [91.7%]</td>
<td></td>
<td>11 [84.6%]</td>
<td>11 [84.6%]</td>
<td></td>
</tr>
<tr>
<td><strong>Current mood stabilizer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1 [7.1%]</td>
<td>1 [8.3%]</td>
<td>0.91</td>
<td>2 [15.4%]</td>
<td>0 [0.0%]</td>
<td>0.14</td>
</tr>
<tr>
<td>No</td>
<td>13 [92.9%]</td>
<td>11 [91.7%]</td>
<td></td>
<td>11 [84.6%]</td>
<td>13 [100.0%]</td>
<td></td>
</tr>
<tr>
<td><strong>Current psychotropic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>8 [57.1%]</td>
<td>10 [83.3%]</td>
<td>0.15</td>
<td>6 [46.2%]</td>
<td>8 [61.5%]</td>
<td>0.43</td>
</tr>
<tr>
<td>No</td>
<td>6 [42.9%]</td>
<td>2 [16.7%]</td>
<td></td>
<td>7 [53.8%]</td>
<td>5 [38.5%]</td>
<td></td>
</tr>
<tr>
<td><strong>Current diabetes medication</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>4 [28.6%]</td>
<td>3 [25%]</td>
<td>0.84</td>
<td>0 [0%]</td>
<td>1 [7.7%]</td>
<td>0.31</td>
</tr>
<tr>
<td>No</td>
<td>10 [71.4%]</td>
<td>9 [75%]</td>
<td></td>
<td>13 [100%]</td>
<td>12 [92.3%]</td>
<td></td>
</tr>
<tr>
<td>Current cholesterol medication</td>
<td>Placebo Non-responders</td>
<td>Placebo Responders</td>
<td>P-value</td>
<td>Infliximab Non-responders</td>
<td>Infliximab Responders</td>
<td>P-value</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>------------------------</td>
<td>-------------------</td>
<td>---------</td>
<td>--------------------------</td>
<td>-----------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Yes</td>
<td>2 [14.3%]</td>
<td>3 [25%]</td>
<td>0.49</td>
<td>1 [7.7%]</td>
<td>3 [23.1%]</td>
<td>0.28</td>
</tr>
<tr>
<td>No</td>
<td>12 [85.7%]</td>
<td>9 [75%]</td>
<td></td>
<td>12 [92.3%]</td>
<td>10 [76.9%]</td>
<td></td>
</tr>
</tbody>
</table>

Results expressed as number [percent] or mean [SD]. BMI: body mass index; CRP: C-reactive protein; HAM-D-17: 17-item Hamilton Depression Rating Scale
Table 2.
Correlations (r, p) between peripheral blood gene expression and plasma biomarkers related to glucose and lipid metabolism.

<table>
<thead>
<tr>
<th>Glucose-related</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene symbol/Marker</td>
<td>Glucose</td>
<td>Insulin</td>
<td>Leptin</td>
<td>Resistin</td>
<td>Adiponectin</td>
</tr>
<tr>
<td>ALDOA</td>
<td>-0.144 (0.317)</td>
<td>0.122 (0.392)</td>
<td>0.317 (0.023)</td>
<td><strong>0.351 (0.013)</strong></td>
<td>0.048 (0.739)</td>
</tr>
<tr>
<td>ENO2</td>
<td>-0.172 (0.233)</td>
<td>-0.074 (0.604)</td>
<td>-0.049 (0.730)</td>
<td>-0.286 (0.047)</td>
<td>-0.007 (0.958)</td>
</tr>
<tr>
<td>ENO3</td>
<td>-0.076 (0.600)</td>
<td>-0.125 (0.381)</td>
<td>-0.148 (0.300)</td>
<td><strong>-0.318 (0.026)</strong></td>
<td>-0.298 (0.034)</td>
</tr>
<tr>
<td>PGAM4</td>
<td>0.154 (0.286)</td>
<td>0.149 (0.296)</td>
<td>0.243 (0.085)</td>
<td><strong>0.372 (0.008)</strong></td>
<td>0.019 (0.896)</td>
</tr>
<tr>
<td>TPI1</td>
<td>-0.021 (0.884)</td>
<td>0.13 (0.362)</td>
<td>0.105 (0.464)</td>
<td>0.280 (0.051)</td>
<td>0.115 (0.422)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lipid-related</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene symbol/Marker</td>
<td>Total Cholesterol</td>
<td>LDL</td>
<td>HDL</td>
<td>Non-HDL</td>
<td>Triglycerides</td>
</tr>
<tr>
<td>LIPA</td>
<td>-0.189 (0.199)</td>
<td>-0.112 (0.435)</td>
<td>-0.226 (0.110)</td>
<td>-0.141 (0.339)</td>
<td>-0.083 (0.571)</td>
</tr>
<tr>
<td>STARD3NL</td>
<td>0.016 (0.916)</td>
<td>0.05 (0.729)</td>
<td><strong>0.386 (0.005)</strong></td>
<td>-0.102 (0.491)</td>
<td>-0.09 (0.539)</td>
</tr>
<tr>
<td>TSPO2</td>
<td>0.264 (0.070)</td>
<td>0.167 (0.241)</td>
<td>-0.174 (0.223)</td>
<td>0.330 (0.022)</td>
<td>0.092 (0.531)</td>
</tr>
</tbody>
</table>

Data are presented as correlation coefficient (r) and p value. Relationships in **bold** were p<0.05 after adjustment for multiple comparisons. ALDOA - aldolase A; ENO2 - enolase 2; LDL - low-density lipoprotein cholesterol; HDL - high-density lipoprotein cholesterol; Non-HDL - non-high-density lipoprotein cholesterol; NEFA - non-esterified fatty acids.